Physician profile
David D Soo
NPI 1467552992
$2,217.97
in general payments reported to CMS, 2019-2025
24 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.25 · 2020: $466 · 2021: $893 · 2022: $90.15 · 2023: $124 · 2024: $206 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $417.14 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $317.67 | 2020-2025 | Farxiga, Airsupra |
| Eisai INC. | $172.88 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.23 | 2020-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $156.76 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.74 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $125.28 | 2020-2021 | |
| Amarin Pharma, INC. | $97.49 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.38 | 2021-2023 | |
| Exact Sciences Corporation | $82.59 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $81.71 | 2023 | Inspire |
| Glaxosmithkline, LLC. | $77.00 | 2021-2025 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Novartis Pharmaceuticals Corporation | $66.83 | 2021 | |
| Amgen INC. | $48.16 | 2020-2025 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $34.16 | 2024-2025 | Gvoke Hypopen |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32.16 | 2020-2021 | |
| Astellas Pharma US INC | $21.79 | 2020 | |
| Radius Health, INC. | $18.65 | 2024 | Tymlos |
| Phathom Pharmaceuticals, INC. | $16.50 | 2025 | Voquezna |
| Allergan, INC. | $14.87 | 2020 | |
| Sumitomo Pharma America, INC. | $14.31 | 2025 | Gemtesa |
| Currax Pharmaceuticals LLC | $14.21 | 2025 | Contrave |
| Genentech USA, INC. | $13.25 | 2019 | |
| Ibsa Pharma INC. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Soo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.